放射疗法HFSRT治疗恶性胶质瘤有效

关键信息

该项II期临床试验评估了一种在标准剂量替莫唑胺和贝伐珠单抗治疗外增加新型大分割立体定向放射治疗(HFSRT)的疗效。在40名新确诊为恶性胶质瘤的患者中，1年总生存率为93%，中位生存时间为19个月。有原神经表型的患者（26%）的客观应答率较低（ORR为14%，其他亚型为77%；P = 0.009）。

在替莫唑胺和贝伐珠单抗治疗外增加一种激进的放射疗法HFSRT，能够使新确诊的恶性胶质瘤患者获得与历史对照相当的总生存率。

TAKE-HOME MESSAGE

This phase II trial evaluated a novel hypofractionated stereotactic radiotherapy (HFSRT) schedule added to standard doses of temozolomide and bevacizumab. In the 40 patients with newly diagnosed glioblastoma, the 1-year overall survival (OS) rate was 93%, with a median of 19 months. Patients with a proneural phenotype (26%) had lower response rates (ORR of 14% compared with 77% for other subclasses; P = .009).

The addition of HFSRT, an aggressive radiotherapy, to temozolomide and bevacizumab achieved an OS comparable to that in historical controls in patients with newly diagnosed glioblastoma.

Clinical Cancer Research

Phase II Study of Bevacizumab, Temozolomide, and Hypofractionated Stereotactic Radiotherapy for Newly Diagnosed Glioblastoma

Clin. Cancer Res 2014 Oct 01;20(19)5023-5031, A Omuro, K Beal, P Gutin, S Karimi, DD Correa, TJ Kaley, LM DeAngelis, TA Chan, IT Gavrilovic, C Nolan, A Hormigo, AB Lassman, I Mellinghoff, C Grommes, AS Reiner, KS Panageas, RE Baser, V Tabar, E Pentsova, J Sanchez, R Barradas-Panchal, J Zhang, G Faivre, CW Brennan, LE Abrey, JT Huse

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

This abstract is available on the publisher's site.

Access this abstract now

Copyright © 2014 Elsevier Inc. All rights reserved.

独家授权，未经许可，请勿转载。